Why This Landed on My Radar
The word “peptide” has been hijacked. On social media it now covers everything from FDA-approved blockbusters your patients genuinely benefit from, to gray-market vials sold with a wink and a Venmo handle. When a patient says “I want to try peptides,” they could mean three completely different things - with three completely different legal and safety profiles. Sorting them is the single most useful thing you can do in that visit. Here’s the field guide.
The Three Buckets
Every “peptide” a patient asks about falls into one of three categories. Learn the buckets and the conversation gets easy.
Bucket 1 - Approved and already in your toolkit. These are the GLP-1-class incretin drugs. Semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) are FDA-approved, manufactured under quality controls, covered by real outcome data, and - depending on the product - indicated for type 2 diabetes and/or chronic weight management. These you can prescribe, monitor, and stand behind. Most patients chasing “peptides for weight loss” are actually candidates for these, and don’t know it.
Bucket 2 - Investigational. Real science, not yet available. This is where retatrutide lives (see Episode 1) - the triple agonist posting category-leading weight-loss numbers in Phase 3, but not FDA-approved and not expected to launch before late 2027. Investigational means studied-in-trials-only. The correct posture: “This is promising and I’m watching it closely; it isn’t something anyone can legitimately prescribe yet, and anything sold as it today isn’t the real thing.”
Bucket 3 - Unapproved “research peptides.” This is the wellness-clinic and online-pharmacy world: BPC-157, CJC-1295, ipamorelin, TB-500, sermorelin, and similar. These are not FDA-approved drugs. Take BPC-157: there is no published human randomized trial demonstrating it’s safe or effective - the marketed benefits come from rat, mouse, and lab studies. The FDA has cautioned against compounded BPC-157 over safety and contamination concerns and placed it on its significant-safety-risk list. Material sold “for research use only” cannot legally be administered to people.
The Compounding Wrinkle You Need to Know
A fair question: “Can’t a compounding pharmacy just make these?” Two separate answers.
For the approved GLP-1s, compounding was widespread only because of drug shortages. The FDA has since declared those shortages resolved (tirzepatide in December 2024, semaglutide in February 2025), which removed the legal basis for routine large-scale compounding of copies. Compounded semaglutide/tirzepatide is now a much narrower and riskier lane than it was a year ago.
For the research peptides, the regulatory ground is actively shifting. A February 2026 HHS review put a slate of peptides - including BPC-157 - back under the microscope, with an FDA advisory committee meeting scheduled for mid-2026. The bottom line for now: the prohibitions remain in force, the picture is changing, and you should verify current status before relying on any of it. I’ll cover exactly where this lands in a later episode once the advisory outcome is public.
The One-Sentence Version for Each Bucket
- Approved (semaglutide, tirzepatide): “We can use this today, and here’s how we’d do it safely.”
- Investigational (retatrutide): “Genuinely exciting, genuinely not available - and worth waiting for the real thing.”
- Unapproved (BPC-157 and friends): “Not an approved drug, no human evidence I can stand behind, and real safety and legal concerns - let’s talk about what actually works.”
What This Means for Your Practice
The patient asking about peptides is not a problem to deflect - they’re a motivated patient who’s already decided they want to do something about their metabolic health. Your job isn’t to say no. It’s to redirect that motivation from Bucket 3 toward Bucket 1, where the evidence and the safety live. That single conversation protects the patient, protects you, and deepens the relationship.
This is Episode 2 of Peptides in Primary Care. Next: candidate selection, titration, and monitoring for the GLP-1s you can prescribe today.
Educational content for clinicians; not medical advice. Regulatory status current as of June 2026 and subject to change - verify before clinical or compounding decisions.